A Platinum Resistance-Related lncRNA Signature for Risk Classification and Prognosis Prediction in Patients with Serous Ovarian Cancer.

Zhu, Yan; Chen, Jiongyu; Zhou, Li; Zhang, Lina; Liu, Yuxin; Zhuang, Yixuan; Peng, Lin; Huang, Yi-Teng.

Afiliação

Zhu Y; Health Care Center, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Chen J; Medical Laboratory, Shenzhen Luohu People's Hospital, Shenzhen 518001, Guangdong, China.
Zhou L; Central Laboratory, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Zhang L; Department of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Liu Y; Health Care Center, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Zhuang Y; Health Care Center, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Peng L; Department of Pathology, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Huang YT; Central Laboratory, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.

J Oncol ; 2022: 7625138, 2022.

Article em En | MEDLINE | ID: mdl-37223641

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article